TABLE 4.

Adjusted changes from baseline on outcome measures

Group	Endpoint	Estimate	SE	95% CI	P a	Effect size
SAS					.0120 b
Treatment-Control	Post-Tx	3.00	0.97	1.06, 4.93	.0029c	0.22
Treatment-Control	6-wk f/u	0.92	1.01	−1.09, 2.94	.3638	0.07
Treatment-Control	12-wk f/u	1.56	1.04	−0.51, 3.63	.1375	0.11
GSE					.0134 b
Treatment-Control	Post-Tx	3.05	1.21	0.64, 5.46	.0139c	0.23
Treatment-Control	6-wk f/u	2.12	1.22	−0.32, 4.55	.0871	0.16
Treatment-Control	12-wk f/u	0.70	1.31	−1.91, 3.31	.5923	0.05
SWLS					.0086 b
Treatment-Control	Post-Tx	3.12	1.40	0.31, 5.92	.0298b	0.06
Treatment-Control	6-wk f/u	2.07	1.41	−0.75, 4.89	.1480	0.04
Treatment-Control	12-wk f/u	−0.13	1.43	−2.99, 2.73	.9279	0.00
PAAS					.8246
Treatment-Control	Post-Tx	0.75	1.08	−1.40, 2.91	.4870	0.05
Treatment-Control	6-wk f/u	0.06	0.84	−1.61, 1.73	.9434	0.00
Treatment-Control	12-wk f/u	−0.04	0.95	−1.94, 1.85	.9649	0.00
FS					.1085
Treatment-Control	Post-Tx	0.39	1.81	−3.23, 4.01	.8317	0.01
Treatment-Control	6-wk f/u	1.20	1.82	−2.44, 4.85	.5119	0.02
Treatment-Control	12-wk f/u	−1.44	1.74	−4.92, 2.04	.4119	0.02
PART-O Summary					.3754
Treatment-Control	Post-Tx	0.10	0.08	−0.07, 0.26	.2488	0.28
Treatment-Control	6-wk f/u	0.14	0.08	−0.02, 0.30	.0944	0.41
Treatment-Control	12-wk f/u	0.13	0.09	−0.05, 0.31	.1588	0.38

Abbreviations: FS, Flourishing Scale; GSE, General Self-Efficacy Scale; PAAS, Personal Advocacy Activity Scale; PART-O, Participation Assessment with Recombined Tools–Objective; Post-Tx, posttreatment; SAS, Self-Advocacy Scale; SE, standard error; SWLS, Satisfaction With Life Scale; wk f/u, week follow-up.

^aP values in bold represent overall group by time interaction effects; P values not in bold represent pair-wise comparisons.

^bSignificance level α = .05.

^cBonferroni adjustment α = .0167 (.05/3).